Featured Research

from universities, journals, and other organizations

Thwarting drug-resistant lung cancer with novel compound

Date:
April 8, 2014
Source:
City of Hope
Summary:
A novel compound, COH-SR4, can target and treat drug-resistant lung cancers, research suggests. The researchers conclude: "the results from our in-vitro and in-vivo studies reveal that COH-SR4 represents a novel candidate ... to target aggressive and drug-resistant lung cancers." They are working on further preclinical research in order to apply for human trials with the Food and Drug Administration, as well studying COH-SR4's ability to fight other cancers, diabetes and obesity.

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

However, a group of City of Hope researchers have identified and synthesized a novel compound -- called COH-SR4 -- that is effective against drug-resistant lung cancer. If its safety and efficacy pan out in future studies, COH-SR4 could play a vital role in treating lung cancers that no longer respond to first-line chemotherapy.

The COH-SR4 findings will be presented at the American Association for Cancer Research (AACR) annual meeting in San Diego on Monday, April 7.

"Based on the chemical structure of COH-SR4, we hypothesized that it caused cancer cell death by inhibiting the antioxidant activity of the mercapturic acid pathway," said Sanjay Awasthi, M.D., professor at City of Hope's Department of Medical Oncology & Therapeutics Research and senior author of the study.

In earlier studies, Awasthi and his colleagues found that nonsmall cell lung cancer and melanoma are responsive to the anti-cancer properties of COH-SR4, which was originally developed to suppress fat cell development and has also been found to improve glucose control and insulin sensitivity.

After observing the cancers' response, the researchers tested COH-SR4 on several types of lung cancer -- including types that are treatment-resistant -- in cell culture and animal models.

In the AACR presentation, Awasthi and his colleagues report that COH-SR4 did lead to lung cancer cell death without showing any toxicity in normal tissue.

Also, in a previously published paper in the journal Biochemical Pharmacology, Awasthi's team found that after two months of administering COH-SR4 orally to animal models, the average mass of lung cancer tumors in the treatment group were less than half of those in the control group (0.77 and 2.02 grams, respectively,) demonstrating that the drug inhibited tumor growth.

Additionally, they confirmed that COH-SR4 did work through inhibition of the mercapturic acid pathway, which then deactivated multiple pathways that protect cancer cells while simultaneously activating pathways that induce cancer cells' self-destruction.

In the paper, they concluded that "the results from our in-vitro and in-vivo studies reveal that COH-SR4 represents a novel candidate ... to target aggressive and drug-resistant lung cancers" and are working on further preclinical research in order to apply for human trials with the Food and Drug Administration, as well studying COH-SR4's ability to fight other cancers, diabetes and obesity.


Story Source:

The above story is based on materials provided by City of Hope. Note: Materials may be edited for content and length.


Cite This Page:

City of Hope. "Thwarting drug-resistant lung cancer with novel compound." ScienceDaily. ScienceDaily, 8 April 2014. <www.sciencedaily.com/releases/2014/04/140408154107.htm>.
City of Hope. (2014, April 8). Thwarting drug-resistant lung cancer with novel compound. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2014/04/140408154107.htm
City of Hope. "Thwarting drug-resistant lung cancer with novel compound." ScienceDaily. www.sciencedaily.com/releases/2014/04/140408154107.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins